
Please try another search
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Margaret G. McGlynn | 65 | 2009 | Independent Director |
Bradley L. Campbell | 48 | 2007 | CEO, President & Director |
Glenn P. Sblendorio | 68 | 2006 | Independent Director |
Michael G. Raab | 59 | 2004 | Chairman & Lead Independent Director |
Lynn Dorsey Bleil | 61 | 2018 | Independent Director |
Michael A. Kelly | 68 | 2020 | Independent Director |
Eiry Wyn Roberts | 61 | 2021 | Independent Director |
Burke W. Whitman | 69 | 2019 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review